 |
| |
| May-23-19 | Upgrade |
Citigroup |
Neutral → Buy |
|
|
| May-21-19 | Initiated |
Credit Suisse |
Outperform |
$208 |
|
| Jan-28-19 | Downgrade |
Evercore ISI |
Outperform → In-line |
|
|
| Oct-01-18 | Initiated |
Cantor Fitzgerald |
Neutral |
$223 |
|
| Apr-05-18 | Reiterated |
Barclays |
Equal Weight |
$190 → $180 |
|
| Feb-12-18 | Reiterated |
Mizuho |
Buy |
$192 → $200 |
|
| Jan-23-18 | Upgrade |
Argus |
Hold → Buy |
|
|
| Nov-01-17 | Downgrade |
Argus |
Buy → Hold |
|
|
| Oct-26-17 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$192 → $188 |
|
| Sep-28-17 | Reiterated |
Mizuho |
Buy |
$183 → $198 |
|
| Sep-15-17 | Initiated |
RBC Capital Mkts |
Sector Perform |
$192 |
|
| Jul-11-17 | Resumed |
Jefferies |
Buy |
|
|
| Jun-23-17 | Initiated |
Deutsche Bank |
Hold |
$172 |
|
| Apr-05-17 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Mar-09-17 | Initiated |
UBS |
Neutral |
$185 |
|
| Feb-01-17 | Upgrade |
BofA/Merrill |
Neutral → Buy |
|
|
| Dec-20-16 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
| Dec-13-16 | Initiated |
Oppenheimer |
Outperform |
|
|
| Nov-08-16 | Initiated |
Mizuho |
Buy |
$164 |
|
| Aug-26-16 | Initiated |
Gabelli & Co |
Hold |
|
|
|
|
| Aug-14-19 04:32PM | Article removed GuruFocus.com |
| 09:36AM | Wednesdays Vital Data: Amgen, American Airlines and Apple InvestorPlace |
| 09:35AM | Amgen (AMGN) Soars to 52-Week High, Time to Cash Out? Zacks |
| 09:28AM | Top Ranked Income Stocks to Buy for August 14th Zacks |
| 09:21AM | Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More Zacks |
| 08:34AM | Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks |
| Aug-13-19 04:45PM | Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales Investor's Business Daily |
| 10:48AM | Here's Why Amgen Stock is Outperforming Its Industry Of Late Zacks |
| 10:43AM | Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks |
| 09:50AM | Should Value Investors Choose Amgen (AMGN) Stock Now? Zacks |
| 09:30AM | Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? Zacks |
| 05:26AM | Will Amgen Continue to Surge Higher? Zacks |
| 04:23AM | Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon TheStreet.com |
| Aug-12-19 04:18PM | The Biggest Biotech Stock Is Approaching A Breakout Here's Why Investor's Business Daily |
| 02:41PM | REFILE-US STOCKS-Wall Street slides on geopolitical, recession fears Reuters |
| 02:21PM | Amgen stock gets boost from Friday ruling on Enbrel MarketWatch |
| 01:26PM | US STOCKS-Wall Street slips on political tensions, recession fears Reuters |
| 01:14PM | Top Analyst Reports: Amgen, Uber, Mondelez & More Zacks |
| 11:38AM | US STOCKS-Wall Street slips on political tensions, recession fears Reuters |
| 09:55AM | US STOCKS-Wall Street slips as trade war stokes fears of recession Reuters |
| 09:44AM | Amgen Wins Enbrel U.S. Patent Litigation Against Novartis Zacks |
| 09:31AM | Amgens Court Win Could Mark a New Dawn for the Stock Barrons.com |
| 09:30AM | Company News For Aug 12, 2019 Zacks |
| 09:07AM | [video]Amgen Climbs After Winning Patent Case on Enbrel TheStreet.com |
| 08:09AM | Top Ranked Income Stocks to Buy for August 12th Zacks |
| 05:33AM | Amgen Rises 5% Investing.com |
| Aug-09-19 04:48PM | US STOCKS-Wall St end down amid more trade woes, high volatility Reuters +5.95% |
| 04:05PM | Amgen Wins Patent Case On Enbrel® (etanercept) PR Newswire |
| 11:35AM | Amgen Rises 3% Investing.com |
| 10:31AM | Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up Zacks |
| 07:26AM | Here's What We Like About Amgen Inc. (NASDAQ:AMGN)'s Upcoming Dividend Simply Wall St. |
| Aug-08-19 09:38AM | Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid Zacks |
| 09:26AM | Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus Zacks |
| 08:34AM | Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down Zacks |
| Aug-07-19 04:31PM | Horizon Stock Pops On Beat And Raise As Another Drugmaker Reverses Investor's Business Daily |
| 06:45AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| Aug-06-19 04:22PM | Biotech ETFs in Focus on Impressive Q2 Earnings Results Zacks |
| 12:54PM | 5 lsquo;Strong Buyrsquo; Dividend Stocks With High Upside Kiplinger |
| 10:19AM | Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up Zacks |
| 10:00AM | Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily |
| Aug-05-19 11:23PM | Arrowhead Research Corp (ARWR) Q3 2019 Earnings Call Transcript Motley Fool |
| 05:59PM | 9 Catalysts That Will Drive Chinese Biotech Stocks Much Higher InvestorPlace |
| 12:53PM | How Drug-Pricing Reforms Could Slam These Biotech Companies Investor's Business Daily |
| 10:33AM | Amgen Falls 3% Investing.com |
| 09:10AM | Is Amgen (AMGN) a Great Value Stock Right Now? Zacks |
| Aug-04-19 03:04PM | 3 Lung Cancer Stocks That Could Soar in September Motley Fool |
| 09:26AM | [video]Amgen Changes the Narrative With Cancer Drug Breakthrough TheStreet.com |
| Aug-02-19 04:00PM | Amgen Announces 2019 Third Quarter Dividend PR Newswire |
| Aug-01-19 12:57AM | Edited Transcript of AMGN earnings conference call or presentation 30-Jul-19 9:30pm GMT Thomson Reuters StreetEvents |
| Jul-31-19 04:21PM | Amgen's Biggest Moneymakers Are Struggling Will A Cancer Drug Fill In? Investor's Business Daily +5.74% |
| 02:41PM | Amgen Gains as Cancer Drug Steals the Show From Legacy Woe Bloomberg |
| 11:51AM | Amgen Tops Forecasters on 2nd-Quarter Earnings GuruFocus.com |
| 11:36AM | Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks |
| 11:09AM | Are Amgen and Gilead Sciences Better Buys After Second-Quarter Earnings? Motley Fool |
| 10:44AM | Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat Zacks |
| 09:34AM | Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine Zacks |
| 09:00AM | Amgens Earnings Werent a Thrill, but Promising Cancer-Drug Results Are Lifting the Stock Barrons.com |
| 07:36AM | Amgen Stock Gains as Analysts Assess Solid Earnings TheStreet.com |
| 07:06AM | The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster Benzinga |
| 05:46AM | Amgen Rises 3% Investing.com |
| 04:25AM | Amgen Inc (AMGN) Q2 2019 Earnings Call Transcript Motley Fool |
| 02:28AM | Apple, Federal Reserve, AMD, General Electric, Qualcomm - 5 Things You Must Know TheStreet.com |
| Jul-30-19 08:40PM | Amgen Manages to Tread Water for Another Quarter Motley Fool |
| 05:28PM | Amgen Stock Rises As Bullish Guidance Outweighs Revenue Dip Investor's Business Daily |
| 05:15PM | Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates Zacks |
| 04:45PM | Amgen results beat estimates, lung cancer trial planned Reuters |
| 04:37PM | UPDATE 3-Amgen results beat estimates, lung cancer trial planned Reuters |
| 04:09PM | Amgen shares inch up on sales, earnings beat MarketWatch |
| 04:05PM | Amgen quarterly revenue dips 3% but profit tops Street expectations Reuters |
| 04:01PM | Amgen Reports Second Quarter 2019 Financial Results PR Newswire |
| 01:52PM | Gilead and Amgen will report second-quarter earnings after the closing bell. Heres what to expect MarketWatch |
| 01:14PM | Merck Shares Rise on Strong Sales Growth GuruFocus.com |
| 01:04PM | Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up Zacks |
| 07:00AM | The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings Benzinga |
| 04:06AM | Amgen boosts earnings guidance amid optimism for new cancer treatment Financial Times |
| Jul-29-19 03:05PM | Pfizer to Combine Off-Patent Drug Business With Mylan GuruFocus.com |
| 10:38AM | Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up Zacks |
| 09:18AM | Why Amgen (AMGN) Might Surprise This Earnings Season Zacks |
| Jul-27-19 12:20PM | 10 Biggest Cancer-Fighting Stocks Motley Fool |
| Jul-26-19 04:00PM | Amgen Controls 98% Of The Shares In Nuevolution After The End Of The Extended Acceptance Period PR Newswire |
| 12:06PM | What's in the Cards for Pfizer (PFE) This Earnings Season? Zacks |
| 11:57AM | AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View Zacks |
| 11:23AM | Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2? Zacks |
| 09:27AM | 5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2 Zacks |
| 08:28AM | Is Amgen (NASDAQ:AMGN) A Risky Investment? Simply Wall St. |
| Jul-25-19 04:00PM | Amgen Announces Webcast Of 2019 Second Quarter Financial Results PR Newswire |
| 01:52PM | UPDATE 1-Drug makers met with Trump to argue against Senate pricing bill Reuters |
| 07:25AM | Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised Zacks |
| Jul-24-19 12:30AM | Is a Beat in the Cards for Celgene's (CELG) Q2 Earnings? Zacks |
| Jul-23-19 05:50PM | Amgen (AMGN) Gains But Lags Market: What You Should Know Zacks |
| 10:44AM | The Zacks Analyst Blog Highlights: UnitedHealth, Citigroup, Honeywell, IBM and Amgen Zacks |
| 10:32AM | Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy? Zacks |
| Jul-22-19 02:31PM | Top Analyst Reports for UnitedHealth, Citigroup & Honeywell Zacks |
| 10:55AM | Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy Zacks |
| 10:19AM | Health Care Digest: Zuckerberg SF General's new insurance partner, a Notable round and more biotech space American City Business Journals |
| Jul-18-19 11:00PM | Amgen And Allergan's MVASI (bevacizumab-awwb) And KANJINTI (trastuzumab-anns) Now Available In The United States PR Newswire |
| 04:13PM | These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger Investor's Business Daily |
| Jul-17-19 10:06AM | Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study Zacks |
| Jul-16-19 02:14PM | Eisai boosts focus on Alzheimer's with new research facility, funding American City Business Journals |
| 07:01AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
|
|
|
|
| Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; Syapse; and DaVita Inc., as well as strategic research partnership with the University of Washington's Institute for Protein Design. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SUGAR RONALD D | Director | Aug 07 | Option Exercise | 54.71 | 2,000 | 109,420 | 16,336 | Aug 08 07:09 PM | | Williams R Sanders | Director | Aug 07 | Sale | 183.04 | 425 | 77,792 | 5,838 | Aug 08 07:12 PM | | SUGAR RONALD D | Director | Aug 07 | Sale | 183.04 | 2,000 | 366,080 | 14,336 | Aug 08 07:09 PM | | SUGAR RONALD D | Director | Jul 03 | Option Exercise | 54.71 | 2,000 | 109,420 | 16,336 | Jul 08 04:23 PM | | SUGAR RONALD D | Director | Jul 03 | Sale | 187.58 | 2,000 | 375,160 | 14,336 | Jul 08 04:23 PM | | SUGAR RONALD D | Director | Jun 05 | Option Exercise | 54.71 | 2,000 | 109,420 | 16,219 | Jun 05 06:55 PM | | SUGAR RONALD D | Director | Jun 05 | Sale | 175.68 | 2,000 | 351,360 | 14,219 | Jun 05 06:55 PM | | SUGAR RONALD D | Director | May 01 | Option Exercise | 54.71 | 2,000 | 109,420 | 15,092 | May 03 05:37 PM | | SUGAR RONALD D | Director | May 01 | Sale | 175.73 | 2,000 | 351,460 | 13,092 | May 03 05:37 PM | | SUGAR RONALD D | Director | Apr 03 | Option Exercise | 54.71 | 2,000 | 109,420 | 15,092 | Apr 03 06:27 PM | | SUGAR RONALD D | Director | Apr 03 | Sale | 193.18 | 2,000 | 386,360 | 13,092 | Apr 03 06:27 PM | | SUGAR RONALD D | Director | Mar 06 | Option Exercise | 54.71 | 2,000 | 109,420 | 14,988 | Mar 08 07:47 PM | | SUGAR RONALD D | Director | Mar 06 | Sale | 188.88 | 2,000 | 377,760 | 12,988 | Mar 08 07:47 PM | | SUGAR RONALD D | Director | Feb 07 | Option Exercise | 54.71 | 2,000 | 109,420 | 14,988 | Feb 11 09:27 PM | | SUGAR RONALD D | Director | Feb 07 | Sale | 190.00 | 2,000 | 380,000 | 12,988 | Feb 11 09:27 PM | | Jacks Tyler | Director | Dec 06 | Option Exercise | 82.60 | 20,000 | 1,652,000 | 28,979 | Dec 10 08:46 PM | | Jacks Tyler | Director | Dec 06 | Sale | 195.41 | 20,000 | 3,908,232 | 8,979 | Dec 10 08:46 PM | | Piacquad David | SVP, Business Development | Nov 30 | Option Exercise | 54.69 | 6,500 | 355,485 | 45,128 | Dec 03 08:13 PM | | Patton Cynthia M | SVP & CCO | Nov 29 | Option Exercise | 54.69 | 1,777 | 97,184 | 23,090 | Dec 03 08:11 PM | | Patton Cynthia M | SVP & CCO | Nov 29 | Sale | 202.88 | 1,777 | 360,520 | 21,313 | Dec 03 08:11 PM |
|
|
|
|
|
|
